Related Experiment Video

Updated: Oct 1, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor

Yulong He1, Ken-Ichi Kozaki, Terhi Karpanen

  • 1Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Haartman Institute and Helsinki University Central Hospital, Biomedicum Helsinki, University of Helsinki, Finland.

Journal of the National Cancer Institute
|June 6, 2002
PubMed
Abstract

Insights

Inhibiting vascular endothelial growth factor receptor 3 (VEGFR-3) signaling suppressed tumor lymphangiogenesis and lymph node metastasis. However, lung metastasis was not affected, suggesting other factors regulate cancer spread.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis Research

Background:

  • Vascular endothelial growth factor C (VEGF-C) drives tumor lymphangiogenesis and metastasis.
  • VEGF-C interacts with VEGF receptor 3 (VEGFR-3) to promote lymphatic vessel formation.
  • Targeting VEGFR-3 signaling is a potential strategy to inhibit tumor spread.

Purpose of the Study:

  • To investigate if inhibiting VEGFR-3 signaling reduces tumor lymphangiogenesis and metastasis.
  • To determine the role of VEGFR-3 in lung cancer metastasis to lymph nodes and lungs.

Main Methods:

  • Used human lung cancer cell lines (NCI-H460-LNM35 and NCI-H460-N15) with varying metastatic capacities.
  • Engineered cell lines to secrete VEGF-C or VEGFR-3-Ig (VEGFR-3 inhibitor).
  • Utilized xenograft mouse models and adenovirus-mediated gene delivery to assess tumor growth, lymphangiogenesis, and metastasis.

Main Results:

  • LNM35 cells showed higher VEGF-C expression and metastatic potential than N15 cells.
  • VEGFR-3 inhibition significantly reduced intratumoral lymphatic vessels and lymph node metastases.
  • Lung metastasis occurred regardless of VEGFR-3 signaling inhibition, indicating alternative spread mechanisms.

Conclusions:

  • VEGFR-3 signaling inhibition effectively suppresses tumor lymphangiogenesis and regional lymph node metastasis.
  • Factors beyond VEGF-C regulate lymph node metastasis.
  • VEGFR-3 inhibition does not prevent lung metastasis, highlighting the complexity of cancer spread.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...